This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis

This study has been withdrawn prior to enrollment.
(Study Terminated Prematurely)
Information provided by (Responsible Party):
Kaiser Permanente Identifier:
First received: May 9, 2006
Last updated: July 31, 2012
Last verified: July 2012
This is a study of the drug tinidazole for women with recurrent bacterial vaginosis. Half of the participants will get the drug for 10 days, the other half will get the drug for 10 days and then twice a week for 12 weeks.

Condition Intervention Phase
Recurrent Bacterial Vaginosis Drug: Oral tinidazole Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis

Resource links provided by NLM:

Further study details as provided by Kaiser Permanente:

Primary Outcome Measures:
  • Efficacy of oral tinidazole for treatment of recurrent bacterial vaginosis
  • Efficacy of oral tinidazole for prevention of recurrent bacterial vaginosis

Secondary Outcome Measures:
  • Patient satisfaction with tinidazole for recurrent bacterial vaginosis

Enrollment: 0
Detailed Description:
This study will recruit 60 women with recurrent bacterial vaginosis. These women must have a current infection to be enrolled in the study and have had two other infections within the past 12 months. After initial screening to make sure that the vaginal symptoms are due to bacterial vaginosis and not the results of a different infection, all of the women will receive tinidazole (a drug that is similar to metronidazole) by mouth for 10 days. At the end of the 10 days, patients will be re-examined. Those women who are free of bacterial vaginosis will enter the second phase of the study, where half of the patients will continue to take tinidazole twice a week for twelve weeks and the other half will take no medication. During this time participants will be examined by the study doctor every 4 weeks to see how effective the treatment has been at preventing the recurrence of bacterial vaginosis. At the end of the 12 weeks, women who are still free of bacterial vaginosis will be seen for 3 more visits over 3 months.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Current infection with bacterial vaginosis
  • 2 previous episodes of bacterial vaginosis within the past 12 months
  • Willing to use contraception
  • Able to swallow pills
  • Willing to refrain from douching or using vaginal products
  • Willing to refrain from alcohol consumption 24 hours before and for 72 hours after taking study medication (tinidazole)

Exclusion Criteria:

  • Women with same sex partners
  • Menstruating at initial exam
  • Presence of yeast, a sexually transmitted disease, or other vaginal infection
  • Purulent cervical discharge
  • Use of any drug for bacterial vaginosis or yeast within the past 2 weeks prior to enrollment
  • Pregnant or nursing
  • Taking lithium
  • Taking blood thinners (anticoagulation therapy)
  • Use of any investigational drug within the previous 30 days
  • Active HPV infection requiring treatment
  • Use of drugs that suppress the immune system
  • History of alcoholism
  • Taking disulfiram
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00324142

United States, California
Kaiser Permanente
San Francisco, California, United States, 94115
Sponsors and Collaborators
Kaiser Permanente
Principal Investigator: Jennifer Gunter, MD Kaiser Permamente
  More Information

Responsible Party: Kaiser Permanente Identifier: NCT00324142     History of Changes
Other Study ID Numbers: CN-06JGunt-01-B
Study First Received: May 9, 2006
Last Updated: July 31, 2012

Keywords provided by Kaiser Permanente:
Bacterial vaginosis

Additional relevant MeSH terms:
Vaginal Diseases
Vaginosis, Bacterial
Genital Diseases, Female
Bacterial Infections
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antitrichomonal Agents
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents processed this record on August 16, 2017